October 15, 2019
Shionogi said on October 11 that it has entered into a new license agreement with US-based Hsiri Therapeutics for an additional joint research program with the aim of discovering and developing novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis...read more